Equitable Trust’s Ligand Pharmaceuticals LGND Stock Holding History

Equitable Trust’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.39M	Sell	4,445 -1,195	-21%	-$353K	0.06%	198
2026 Q2	$1.78M	Buy	5,640 +605	+12%	+$143K	0.07%	179
2026 Q1	$1.01M	Hold	5,035	–	–	0.05%	230
2025 Q4	$952K	Sell	5,035 -880	-15%	-$169K	0.04%	242
2025 Q3	$1.05M	Sell	5,915 -330	-5%	-$49.1K	0.05%	226
2025 Q2	$710K	Buy	6,245 +1,710	+38%	+$183K	0.04%	272
2025 Q1	$477K	Buy	4,535 +755	+20%	+$85.4K	0.03%	313
2024 Q4	$405K	Sell	3,780 -300	-7%	-$33.9K	0.02%	360
2024 Q3	$408K	Hold	4,080	–	–	0.03%	346
2024 Q2	$344K	Buy	+4,080	New	+$325K	0.02%	358

Other funds holding LGND

Congress Asset Management Boston, Massachusetts $15.4B AUM 30.35% 1-Year Est. Return

Chicago Capital Chicago, Illinois $4.32B AUM 31.14% 1-Year Est. Return

Essex Investment Management Boston, Massachusetts $675M AUM 61.81% 1-Year Est. Return

Woodstock Corp Boston, Massachusetts $1.24B AUM 22.02% 1-Year Est. Return

Moody National Bank Trust Division Galveston, Texas $1.21B AUM 28.25% 1-Year Est. Return

Linden Thomas Advisory Services Charlotte, North Carolina $1.26B AUM 37.95% 1-Year Est. Return

State of Alaska Department of Revenue Juneau, Alaska $9.6B AUM 34.67% 1-Year Est. Return

TAM

Tealwood Asset Management Minneapolis, Minnesota $251M AUM 42.58% 1-Year Est. Return

Portside Wealth Group Provo, Utah $901M AUM 21.06% 1-Year Est. Return

Atria Investments Charlotte, North Carolina $10.3B AUM 19.62% 1-Year Est. Return

Equitable Trust's LGND Position: Q3 2026 in Review

Equitable Trust reduced its Ligand Pharmaceuticals (LGND) stake by 21% in Q3 2026, selling an estimated $353K and leaving 4,445 shares worth $1.39M. The position accounts for 0.06% of the portfolio, ranked #198.

Equitable Trust first reported a position in LGND in Q2 2024 and has held it in 10 quarters since. The position peaked at $1.78M in Q2 2026. 45 funds tracked by Wall St. Rank hold LGND as of Q3 2026.

Equitable Trust held 4,445 shares of Ligand Pharmaceuticals worth $1.39M as of Q3 2026.
Equitable Trust sold 1,195 Ligand Pharmaceuticals shares in Q3 2026, an estimated $353K.
Ligand Pharmaceuticals made up 0.06% of Equitable Trust's portfolio in Q3 2026, its #198 holding.
Equitable Trust first reported a position in Ligand Pharmaceuticals in Q2 2024 and has held it in 10 quarters since.
Equitable Trust's Ligand Pharmaceuticals position peaked at $1.78M in Q2 2026.
45 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2026.

Based on Equitable Trust's 13F filing for Q3 2026, filed 13 Oct 2026.